Avenanthramide C
Based on 1 publication(s) in Google Scholar
Avenanthramide C is an orally active polyphenolic compound that penetrates the blood-brain barrier. Avenanthramide C is derived from oats. Avenanthramide C inhibits NF-κB nuclear translocation and inhibits the phosphorylation of PI3K, PLCγ1, Lyn, Syk, and Akt. Avenanthramide C inhibits the expression and activity of MMP-9 and inhibits MAPK phosphorylation. Avenanthramide C scavenges DPPH radicals, reduces intracellular ROS, and inhibits pro-inflammatory cytokine release and adhesion molecule expression. Avenanthramide C inhibits cell degranulation. Avenanthramide C attenuates active systemic anaphylaxis and inhibits passive cutaneous anaphylaxis. Avenanthramide C ameliorates PHZ-induced blood stasis. Avenanthramide C inhibits neuroinflammation, restores long-term potentiation, and improves recognition and spatial memory in Alzheimer's disease models. Avenanthramide C can be used for research on allergic inflammation, thrombosis, atherosclerosis, and Alzheimer's disease.
For research use only. We do not sell to patients.
- Purity: 99.13%
- CAS No.: 116764-15-9
- Formula: C16H13NO6
- Molecular Weight:315.28
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Avenanthramide C
MoreAll Phospholipase Isoforms
More
Biological Activity
Description
|
Lyn |
MMP-9 |
In Vitro
Avenanthramide C (0.01-100 µM; 12 h) is not cytotoxic up to 100 µM in RBL-2H3 cells[1].
Avenanthramide C (1-100 nM; 1 h) concentration-dependently inhibits β-hexosaminidase release in DNP-HSA-stimulated RBL-2H3 cells[1].
Avenanthramide C (1-100 nM; 1 h) concentration-dependently inhibits histamine release in DNP-HSA-stimulated RBL-2H3 cells[1].
Avenanthramide C (1-100 nM) suppresses DNP-HSA-stimulated intracellular calcium elevation in a concentration-dependent manner in RBL-2H3 cells[1].
Avenanthramide C (1-100 nM; 1 h) inhibits DNP-HSA-stimulated phosphorylation of PI3K and PLCγ1 in RBL-2H3 cells[1].
Avenanthramide C (1-100 nM; 1 h) concentration-dependently inhibits the gene expression and release of IL-4, IL-6, and TNF-α in DNP-HSA-stimulated RBL-2H3 cells[1].
Avenanthramide C (1-100 nM; 1 h) inhibits the phosphorylation of Lyn, Syk, and Akt and suppresses IκBα degradation and NF-κB nuclear translocation in DNP-HSA-stimulated RBL-2H3 cells[1].
Avenanthramide C (0-100 μM; 24 h) dose-dependently suppresses the TNF-α-induced increase in MMP-9 mRNA levels in HASMC cells[3].
Avenanthramide C (100 μM) inhibits the MAPK signaling pathway by decreasing phosphorylation of ERK, JNK, and p38, and reduces IκB phosphorylation in TNF-α-stimulated HASMC cells[3].
Avenanthramide C (50 μM; 2 h) restores impaired LTP in ex vivo hippocampal slices from 5XFAD mice[5].
Avenanthramide C (50 μM; 2 h) restores impaired LTP in ex vivo hippocampal slices from Tg2576 mice[5].
Avenanthramide C (1.0625-100 μg mL-1; 30 min) acts as a potent free radical scavenger in the cell-free DPPH assay with an IC50 of 7.38 μg mL-1[2].
Avenanthramide C (6.25-100 μg mL-1; 24 h) is non-toxic to HUVECs at concentrations up to 25 μg mL-1 but exhibits cytotoxic effects at 50 and 100 μg mL-1[2].
Avenanthramide C (6.25-25 μg mL-1; 24 h) dose-dependently attenuates intracellular ROS accumulation induced by t-BOOH in HUVECs[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:RBL-2H3 cells
-
Concentration:0.01-100 µM
-
Incubation Time:12 h
-
Result:Did not show any cytotoxicity up to 100 µM.
-
Cell Line:RBL-2H3 cells
-
Concentration:100 nM
-
Incubation Time:1 h (pre-treatment); 15 min (stimulation)
-
Result:Inhibited DNP-HSA-stimulated phosphorylation of PI3K and PLCγ1.
-
Cell Line:RBL-2H3 cells
-
Concentration:1-100 nM
-
Incubation Time:1 h (pre-treatment); 1 h (gene expression); 6 h (protein release)
-
Result:Inhibited the gene expression and release of pro-inflammatory cytokines (IL-4, IL-6, and TNF-α) in a concentration-dependent manner.
-
Cell Line:HUVECs
-
Concentration:0, 6.25, 12.5, 25, 50, and 100 μg mL-1
-
Incubation Time:24 h
-
Result:Showed no significant toxicity at concentrations below 25 μg mL-1.
At 50 and 100 μg mL-1, a marked reduction in cell viability was observed.
-
Cell Line:Human Aortic Smooth Muscle Cells (HASMC)
-
Concentration:0, 50, 100 μM
-
Incubation Time:24 h
-
Result:Dose-dependently suppressed the TNF-α-induced increase in MMP-9 mRNA levels in HASMC cells.
In Vivo
Avenanthramide C (0.1-10 mg/kg; p.o.; single dose; 1 h before DNP-HSA challenge) dose-dependently inhibits IgE-mediated passive cutaneous anaphylaxis[1].
Avenanthramide C (6 mg/kg; p.o.; daily; 2 weeks) rescues impaired long-term potentiation in 5XFAD Alzheimer's disease model mice[5].
Avenanthramide C (6 mg/kg; p.o.; daily; 2 weeks) rescues impaired long-term potentiation in Tg2576 Alzheimer's disease model mice[5].
Avenanthramide C (6 mg/kg; p.o.; once daily; 2 weeks) inhibits neuroinflammation in the hippocampus of 5XFAD and Tg2576 Alzheimer's disease model mice[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Imprinting Control Region (ICR) mice (male, 30-35 g, 6 weeks old)[1]
-
Dosage:0.1, 1, and 10 mg/kg
-
Administration:p.o.; on days 9, 11, and 13
-
Result:Dose-dependently increased the rectal temperature.
Reduced the serum histamine level.
Suppressed the increased serum levels of total IgE, OVA-specific IgE, and IL-4.
-
Animal Model:Imprinting Control Region (ICR) mice (male, 30-35 g, 6 weeks old)[1]
-
Dosage:0.1, 1, and 10 mg/kg
-
Administration:p.o.; single dose; 1 h before DNP-HSA challenge
-
Result:Decreased the PCA reaction (ear swelling and plasma extravasation) in a dose-dependent manner.
-
Animal Model:AB strain (2 days post-fertilization)[2]
-
Dosage:12.5, 25, 50 μg mL-1
-
Administration:in water; 24 hours
-
Result:Improved PHZ-induced blood stasis and reduced caudal vein thrombosis.
Enhanced cardiac red blood cell intensity.
Achieved antithrombotic ability of 6.7%, 25.4%, and 50.4% at 12.5, 25, and 50 μg mL-1, respectively.
-
Animal Model:C57BL/6J (male, 7-8 months old, wild-type); 5XFAD (male, 5-6 months old, transgenic)[5]
-
Dosage:6 mg/kg
-
Administration:p.o.; daily; 2 weeks
-
Result:Increased long-term potentiation in hippocampal slices.
Suppressed cleaved caspase-3 levels.
Increased p-GSK3β (Ser9) levels to levels comparable to wild-type controls.\nImproved object recognition memory with a preference index comparable to wild-type counterparts.
Significantly increased time spent in the target quadrant and increased number of platform crossings in the Morris water maze probe test.
-
Animal Model:C57BL/6J (male, 7-8 months old, wild-type); Tg2576 (male, 7-8 months old, transgenic)[5]
-
Dosage:6 mg/kg
-
Administration:p.o.; daily; 2 weeks
-
Result:Restored impaired long-term potentiation in hippocampal slices.
Restored GSK3β (Ser9) and caspase-3 active forms to basal levels.
-
Animal Model:C57BL/6J (male, wild-type); 5XFAD (male, 5-6 months old, transgenic); Tg2576 (male, 7-8 months old, transgenic)[5]
-
Dosage:6 mg/kg
-
Administration:p.o.; daily; 2 weeks
-
Result:Significantly reduced levels of activated microglia marker Iba1 in the hippocampus.
Significantly suppressed hippocampal levels of TNFα and IL-6.
Increased levels of IL-10.
Decreased phospho-forms of IKK and P65.
Chemical Information
-
CAS No. 116764-15-9
-
Appearance Solid
-
Molecular Weight 315.28
-
Formula C16H13NO6
-
Color Light yellow to brown
-
SMILES
O=C(C1=CC(O)=CC=C1NC(/C=C/C2=CC=C(C(O)=C2)O)=O)O
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
Solvent & Solubility
In Vitro:
DMSO : 50 mg/mL (158.59 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.93 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.93 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (297 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[4]. Matsukawa T, et al. Occurrence of avenanthramides and hydroxycinnamoyl-CoA:hydroxyanthranilate N-hydroxycinnamoyltransferase activity in oat seeds. Zeitschrift fur Naturforschung. C, Journal of biosciences. 2000;55(1-2):30-6. [Content Brief]
[5]. Ramasamy VS, et al. Avenanthramide-C Restores Impaired Plasticity and Cognition in Alzheimer's Disease Model Mice. Molecular neurobiology. 2020 Jan;57(1):315-330. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.1718 mL | 15.8589 mL | 31.7178 mL | 79.2946 mL |
| 5 mM | 0.6344 mL | 3.1718 mL | 6.3436 mL | 15.8589 mL | |
| 10 mM | 0.3172 mL | 1.5859 mL | 3.1718 mL | 7.9295 mL | |
| 15 mM | 0.2115 mL | 1.0573 mL | 2.1145 mL | 5.2863 mL | |
| 20 mM | 0.1586 mL | 0.7929 mL | 1.5859 mL | 3.9647 mL | |
| 25 mM | 0.1269 mL | 0.6344 mL | 1.2687 mL | 3.1718 mL | |
| 30 mM | 0.1057 mL | 0.5286 mL | 1.0573 mL | 2.6432 mL | |
| 40 mM | 0.0793 mL | 0.3965 mL | 0.7929 mL | 1.9824 mL | |
| 50 mM | 0.0634 mL | 0.3172 mL | 0.6344 mL | 1.5859 mL | |
| 60 mM | 0.0529 mL | 0.2643 mL | 0.5286 mL | 1.3216 mL | |
| 80 mM | 0.0396 mL | 0.1982 mL | 0.3965 mL | 0.9912 mL | |
| 100 mM | 0.0317 mL | 0.1586 mL | 0.3172 mL | 0.7929 mL |
Avenanthramide C Related Classifications
HY-124344 Related Classifications
Powered by Bioz